The limited efficacy and negative side-effects associated with current therapeutics for Hepatitis B and C are highlighting the urgent need for new, improved alternatives. Combination therapies offering better clinical outcomes are coming to the fore and look set to transform the European market for Hepatitis B and C.
New analysis from Frost & Sullivan (lifesciences.frost.com), Analysis of European Hepatitis B and C Therapeutics Markets, finds that the Hepatitis B market earned revenues of $1.26 billion in 2012 and estimates this to reach $1.89 billion in 2019, while the Hepatitis C market is projected to expand from $2.40 billion to $3.66 billion over the same time period. The therapeutic segments covered include interferons and nucleoside analogues for Hepatitis B, and Standard of Care (Peginterferon alfa and Ribavirin) and protease inhibitors for Hepatitis C.
The side effects associated with interferon-based therapeutics such as fever, headache, fatigue, muscle and joint pain, shivering, and the ineffective response to Hepatitis C Virus (HCV) genotype 1 patients are motivating the development of combination therapies.
"Improved drug efficiency, reduced pill burden and lower dosage frequency are among the common advantages related to the use of combination drugs," notes Frost & Sullivan Healthcare Research Analyst Deepika Pramod Chopda. "For instance, the combined use of interferon and interferon-free treatments is expected to yield positive results among infected patients; ribavirin-long acting interferons combination is estimated to boost the therapeutic success rate by over 50-60%."
The market is responding swiftly to the demand for improved therapeutic offerings. There has been an increase in new classes of compounds such as protease inhibitors, NS5a inhibitors, and nucleotide polymerase inhibitors for interferon-free treatment of HCV and Hepatitis B Virus (HBV).
At the same time, wider access to personalised medical treatment is encouraging the uptake of novel, improved therapeutics. The availability of drugs that target viral hepatitis infections according to distinct genetic strains is promoting market development.
HBV and HCV are prevalent among illegal drug users and migrant populations across Europe. However, low awareness means that many affected patients remain untreated.
"Wider access to national counselling programmes and enhancing awareness among high-risk populations such as drug users, infected mothers, and migrants is critical," concludes Chopda. "Such initiatives, together with free screening and reduced treatment costs, will help limit the incidence and impact of Hepatitis B and C."
If you are interested in more information on this research, please send an email to Anna Zanchi, Corporate Communications, at anna.zanchi[.]frost.com
Analysis of the European Hepatitis B and C Therapeutics Market is part of the Life Sciences Growth Partnership Service programme. Frost & Sullivan’s related research services include: European HIV Drugs Market, European Hepatitis B and C Diagnostics Market, U.S. Hepatitis C Market, and U.S HIV/AIDS Therapies Market. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.
About Frost & Sullivan
Frost & Sullivan (frost.com), the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.
Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organisation prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
Contact Us: Start the discussion | Join Us: Join our community | Subscribe: Newsletter on "the next big thing" | Register: Gain access to visionary innovation.